These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26592057)

  • 1. In vitro activity of cefepime against extended spectrum p-lactamase-producing Escherichia coli and Klebsiella pneumoniae from clinical specimens at Bugando Medical Centre, Mwanza, Tanzania.
    Mshana SE; Kidenya BR; Kataraihya JB
    Tanzan J Health Res; 2011 Oct; 13(4):119-21. PubMed ID: 26592057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.
    Nepal K; Pant ND; Neupane B; Belbase A; Baidhya R; Shrestha RK; Lekhak B; Bhatta DR; Jha B
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):62. PubMed ID: 28927454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.
    Hu F; Wu W; Ye X; Xu X; Zhu D
    Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1297-9. PubMed ID: 20549530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Duttaroy B; Mehta S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
    Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
    Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Korea.
    Jung Y; Lee SS; Song W; Kim HS; Uh Y
    Diagn Microbiol Infect Dis; 2019 May; 94(1):88-92. PubMed ID: 30658867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi.
    Taneja J; Mishra B; Thakur A; Dogra V; Loomba P
    J Infect Dev Ctries; 2010 Sep; 4(8):517-20. PubMed ID: 20818104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG; Bhavnani SM; Jones RN
    Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and genotypic detection of ESBL mediated cephalosporin resistance in Klebsiella pneumoniae: emergence of high resistance against cefepime, the fourth generation cephalosporin.
    Grover SS; Sharma M; Chattopadhya D; Kapoor H; Pasha ST; Singh G
    J Infect; 2006 Oct; 53(4):279-88. PubMed ID: 16488476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extended-spectrum beta-lactamase (ESBL) produced by Escherichia coli and Klebsiella pneumoniae isolated from Teikyou University Hospital--the first report].
    Kawakami S; Ono Y; Yamamoto M; Matumura M; Okamoto R; Inoue M; Miyazawa Y
    Kansenshogaku Zasshi; 1999 Nov; 73(11):1110-5. PubMed ID: 10624090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.